S&P Futures
5,971.25 +13.00 (+0.22%) Dow Futures
44,002.00 +101.00 (+0.23%) Nasdaq Futures
20,961.75 +67.75 (+0.32%) Russell 2000 Futures
2,412.90 +7.10 (+0.30%) Crude Oil
71.91 +0.22 (+0.31%) Gold
2,662.90 -13.40 (-0.50%)
Theriva Biologics, Inc. (TOVX)
After hours:
| Previous Close | 1.9700 |
| Open | 1.8800 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 800 |
| Day's Range | 1.8900 - 2.0700 |
| 52 Week Range | 1.2400 - 17.0000 |
| Volume | |
| Avg. Volume | 3,439,746 |
| Market Cap | 4.477M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -31.2500 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 100.00 |
GlobeNewswireTheriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced selection as one of five finalists for Merck KGaA's EMEA Advance Biotech Grant. Finalists for the grant will present to a six-judge panel from Merck’s Emerging Biotech group during BIO Europe 20
- GlobeNewswire
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva’s systemic, selective, stroma-degrading oncolytic adenovir
